Tradestie Institutional Equity Comparison Engine

EIKN vs BCAX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BCAX Overall Edge

BCAX Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bicara Therapeutics Inc. Common Stock (BCAX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, EIKN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BCAX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EIKN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EIKN N/M vs BCAX N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner BCAX
1Y -64.1% vs -31.6% ยท 52W Pos 3% vs 8%
Options & Structure Winner BCAX
UNCLASSIFIED (N/A IV) vs BREAKDOWN (23rd %ile IV)
EIKN US Equity
EIKN
Institutional Equity
$5.38
-9.95% 1D
Market Cap N/A
1M Return -27.43%
1Y Return -64.1%
Forward P/E N/M
Unified AI Score
43.2 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EIKN -64.1% BCAX -31.63% Spread: +28.67 pp (BCAX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EIKN TTM Op. Margin: N/A BCAX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EIKN vs BCAX. Trailing 12-month operating profitability (EIKN N/A vs BCAX 0.0%) and valuation multiples (EIKN N/M vs BCAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EIKN (1) vs BCAX (7)
Institutional Metric EIKN BCAX Criterion Row Winner
Market Capitalization Scale N/A $665.2M Larger Scale BCAX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth BCAX
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin BCAX
Net Profit Margin Profitability N/A 0.0% Higher Margin BCAX
Return on Equity (ROE) Capital Efficiency N/A -54.2% Higher ROE BCAX
52-Week Range Position Momentum 3% ($5โ€“$17) 8% ($8โ€“$31) Stronger Trend BCAX
Beta / 30D Volatility Risk Regime 2.05ฮฒ ยท 133% Vol 1.42ฮฒ ยท 184% Vol Lower Realized Risk EIKN
Unified Institutional Score Composite Signal 43.2 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EIKN vs BCAX Buy Guide
EIKN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EIKN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EIKN nor BCAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.